Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
4
3
0
0
CinCor Pharma, Inc. Share · US17240Y1091 · CINC (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CinCor Pharma, Inc.
Analyst Grade Summary
No Price
Share Float & Liquidity
Free Float 40,92 %
Shares Float 17,91 M
Shares Outstanding 43,76 M
Company Profile for CinCor Pharma, Inc. Share
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Company Data
Name CinCor Pharma, Inc.
Company CinCor Pharma, Inc.
Symbol CINC
Website
https://www.cincor.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN US17240Y1091
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Marc M. P. de Garidel
Market Capitalization 1 Mrd.
Country United States of America
Currency USD
Employees 0,0 T
Address 200 Clarendon Street, 02116 Boston
IPO Date 2022-01-07
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | CINC |
More Shares
Investors who hold CinCor Pharma, Inc. also have the following shares in their portfolio:
